Dupixent Information for Healthcare Professionals

Skip to main content

This is a promotional website, intended only for healthcare professionals from the United Kingdom (UK) & Republic of Ireland (RoI).

For members of the public:
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

For Healthcare professionals in the United Kingdom:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on
Tel: +44 (0) 800 0902 314.
Alternatively, send via email to UK-drugsafety@sanofi.com

For Healthcare professionals in the Republic of Ireland:
Adverse events should be reported. www.hpra.ie email: medsafety@hpra.ie Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to IEPharmacovigilance@sanofi.com

Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.
Copyright © 2023 Aventis Pharma Limited. All rights reserved.

MAT-GB-2102758 (v8.0) | Date of preparation: April 2023

DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

DUPIXENT can be used with or without topical corticosteroids.

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications: hypersensitivity to DUPIXENT or to any ingredient in the formulation.

Other relevant warnings and precautions regarding: driving or operating machinery; systemic hypersensitivity reactions; live vaccines; conjunctivitis and keratitis; helminth infection; concomitant atopic conditions; pregnant and nursing women; geriatric patients.

Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

Please see DUPIXENT Product Monograph for complete prescribing information.

Indication and clinical use:

DUPIXENT (dupilumab injection) is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.

• No dose adjustment is recommended for elderly patients.
• Safety and efficacy in pediatric patients have not been established.

Contraindications:

Hypersensitivity to DUPIXENT or to any ingredient in the formulation or component of the container.

Warnings and precautions:

• Reduction of corticosteroid dosage
• Systemic hypersensitivity reactions
• Elevation of blood eosinophils
• Not studied with live vaccines
• Conjunctivitis and keratitis
• Patients with helminth infection
• Patients with comorbid asthma
• Pregnant and nursing women
• Geriatric patients

For more information:

Consult http://products.sanofi.ca/en/dupixent-en.pdf for important information relating to adverse drug reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-589-6215.

Please see DUPIXENT Product Monograph for complete prescribing information.

You are about to leave this website.

This link takes you to a third party website. Sanofi has no control over the content of the website you are about to access. The terms of usage of the third party website will differ from that of the www.dupixent.co.uk. It is recommended that you carefully read the legal notice, cookies and privacy policy of third party websites before accessing these sites.

By continuing you are acknowledging that you have read this notice.

MAT-XU-2204625 (v1.0) | Date of preparation: December 2022

CONTINUE